SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Autres langues Shanghai Shyndec Pharmaceutical Co., Ltd.

Actions

600420

CNE000001JG2

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 08/05/2024			Varia. 5j.	Varia. 1 janv.
11,74 ^CNY	-1,26 %		+7,90 %	+19,92 %

29/04	Shanghai Shyndec Pharmaceutical Co. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
15/04	Les actions chinoises augmentent après l'adoption de nouvelles lignes directrices ; les actions de Hong Kong chutent	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	16/04
China stocks rise after new guidelines; HK shares drop	15/04
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	10/04
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	27/03
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine	07/03
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	21/02
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	20/02
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/01
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	03/01
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets	08/12
Shyndec Pharma Passes Drug GMP Compliance Inspection	28/11
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid	08/11
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation	07/11
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing	19/09/23
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index	18/09/23
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient	14/09/23
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/07/23
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection	06/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shanghai Shyndec Pharmaceutical Co., Ltd.

Actions

600420

CNE000001JG2

Autres langues

Filtres